Trial Profile
Long term outcomes of pulmonary arterial hypertension induced by Dasatinib: a retrospective study from French Pulmonary Hypertension Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 04 Aug 2017 New trial record
- 01 Jul 2017 Results published in the European Respiratory Journal